Importantly, the cancer-predisposing C61G mutation in BRCA1, which abrogates its E3 ubiquitin ligase activity, and disrupts the BRCA1 RING domain and its interaction with BARD1 (Drost et al, 2011), did not significantly alter the frequency of fusions induced by TRF2 depletion. This evidence concerns the gene BARD1 and cancer.